Analytical Applications - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Analytical Applications
Several industry experts describe applications in pharmaceutical applications, including on-line total organic carbon analysis, ultra-fast liquid chromatography, rapid microbial testing, and differential scanning calorimetry-Raman Spectroscopy.

Pharmaceutical Technology
Volume 34, pp. s36-s30

Case study : in-process sterility testing . Because of the ubiquity of AK in living organisms, AK-amplified assays can detect bacteria, molds, and yeasts, and this microbial testing is used in sterility testing to determine product release (4, 5). A company was testing its sterile, in-process materials using a 14-day sterility test. A comparability test was performed to see if equivalent results could be obtained using a rapid method. Spiking studies were conducted by inoculating samples at a level approximating 1 colony-forming unit (CFU). Following inoculation, the samples were enriched for 24 h, and contamination was detected using a rapid microbial system (Celsis AKuScreen). Microbial hold times and the corresponding time for quarantined inventory was 48 h, a savings of 12 days over traditional microbial testing.

Case study: mold detection. Pharmaceutical companies use microbial specifications that are based on United States Pharmacopeia, European Pharmacopoeia, and Japanese Pharmacopoeia guidelines, product history, and risk profile. With respect to mold, this typically means the ability to detect Aspergillus brasiliensis. Slow-growing, molds are often the rate-determining step for product release. AK-amplified assays (e.g., Celsis AKuScreen) can detect yeast and mold in 24 h compared with 48 h if standard bioluminescence is used or 4–7 days if using traditional methods.

Table I (rapid microbial testing): Detection times for slow-growing mold.* (TABLE 1 (RAPID MICROBIAL TESTING) IS COURTESY OF CELSIS)
One company used standard ATP screening placed microbial specifications on certain products to include the detection of Penicillum expansum. The company modified its bioluminescence protocol using a rapid microbial system. A study was performed on a water-based lotion, examining how broth type, incubation temperature, and conditions affect A. brasiliensis and P. expansum detection using standard bioluminescence and AK-amplified reageants (e.g., Celsis AKuScreen). Preliminary studies indicated that static incubation at room temperature optimized the growth of P. expansum. Table 1 (rapid microbial testing) summarizes the study data in which the samples were inoculated with < 50 spores of P. expansum and incubated statically at room temperature (24–27 C). The modifications of room temperature incubation and broth changes to letheen or malt extract broth (MEB) enabled detection with the AKuScreen reagents within 24 h. Detection with standard bioluminescence required 48 h using MEB and 72 h in letheen under the same incubation conditions.

Rapid microbial testing section references

1. B.S. Riley, Am. Pharm. Rev, 7 (2), 28–31 (2004).

2. D.J. Squirrel et al., Anal. Chim. Acta 457 (1), 109–114 (2002).

3. D.J. Squirrel and M.J. Murphy, "A Practical Guide to Industrial Uses of ATP-Luminescence" in Rapid Microbiology (Cara Technology, Lingfield, Surrey, UK, 1997).

4. L. Noda, Adenylate Kinase: The Enzymes (Vol. 8) ( Academic Press, New York, 1973), p. 279–305.

5. G.E. Shultz, Cold Spring Harbor Symposia on Quantitative Biology, 52 , 429–439 (1987).

6. L. Dane, "Study Results: Modifications to Detect P. expansum in 24 Hours Using AKuScreen Reagents" (Celsis, Chicago, 2006).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here